AIM movers: MS International German Navy contract and Hardide beats expectations
Sulfur battery expertise developer Gelion (LON: GELN) reported full 12 months outcomes forward of expectations with revenues of £2.46m and a pre-tax lack of £5.33m. Net money was £7.55m on the finish of June 2026 and that ought to cowl the following monetary 12 months. Earlier this week, there was optimistic information of the impartial testing of its Nano-Encapsulated Sulfur (NESTM) Cathode Active Material (CAM) by National Laboratory of the Rockies (NLR) underneath the Cooperative Research and Development Agreement (CRADA), which confirmed Gelion’s personal assessments of its expertise. The share value gained 12.55 to 18p.
Orcadian Energy (LON: ORCA) shares have risen 10.7% to fifteen.5p on the again of the UK authorities approval for the event of the Jackdaw undertaking within the North Sea. This might have a optimistic impact on the flexibility to achieve approval for Oracadian Energy’s Earlham undertaking.
– Advertisement –
MS International (LON: MSI) has received a £29.7m contract to produce 12 DS30M gun methods to the German Navy. This shall be equipped over an unspecified variety of years. Last 12 months’s group revenues have been £72m. The share value elevated 9.69% to £15.85.
Cancer therapies developer ValiRx (LON: VAL) factors out the announcement that Ambrose Healthcare is buying AM-Pharma. Ambrose has a licence for VAL401 from 54.1% owned ValiSeek. As a part of that settlement ValiSeek acquired 576,000 shares in Ambrose so as to add to the 75,000 shares it had already acquired. ValiRx believes that the acquisition might assist with progressing the regulatory course of for VAL401. The share value added 9.37% to 0.175p.
Surface coatings supplier Hardide (LON: HDD) says full 12 months revenues greater than doubled to £13.5m and pre-tax revenue was £4.9m, which is barely higher than anticipated. Further orders have been just lately received. and they’ll contribute to 2026-27. Hardide is investing in doubling capability. The share value improved 9.13% to 113.5p.
FALLERS
Education providers supplier Malvern International (LON: MLVN) says underlying full 12 months revenues improved from £12.6m to £14.4m. However, there was a swing from a small optimistic EBITDA to a lack of £2.5m, together with a £700,000 loss on the closed Adult English Language Teaching (ELT) corporate affairs. Net money was £700,000 on the finish of September 2026. An extra loss is predicted this 12 months. The share value dived 29.3% to 7.25p.
Cancer diagnostics firm CelLBxHealth (LON: CLBX) has lowered full 12 months revenues steering to £1.8m on account of proceeds recognition and industrial supply delays. Guidance for subsequent 12 months is £3m-£4m. Cost reductions imply that the nine-month working loss has been minimize from £9.7m to £4m. Cash will final into the primary quarter of 2027. The share value slid 19.4% to 0.625p.
Brazil-focused gold miner Serabi Gold (LON: SRB) says third quarter manufacturing was decrease than anticipated at 11,000 ounces, which was the identical because the earlier quarter. Total gold manufacturing in 2026 is anticipated to be 44,200 ounces. Permitting delays have hampered manufacturing. Cash was $63.2m on the finish of September 2026. The share value declined 15.6% to 190p.
Building supplies provider SigmaRoc (LON: SRC) continues to do nicely in a weak development market. Nine-month revenues have been 2.5% forward and margins are edging up. Zeus maintains its 2026 pre-tax revenue forecast at £162m, up from £154m final 12 months. The acquisition of AB Dolomitas ought to full by the top of the 12 months. That will increase subsequent 12 months’s earnings. The share value dipped 6.37% to 116.1p.
